A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-Ht(2A) serotonin receptor but does not participate in activation via a 'salt-bridge disruption' mechanism

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 3, 2000, Pages 735-736

  Kristiansen, Kurt ^a,c   Kroeze, Wesley K ^a   Willins, David L ^a   Gelber, Edward I ^a   Savage, Jason E ^a   Glennon, Richard A ^b   Roth, Bryan L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 2A RECEPTOR; TRYPTAMINE DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; DRUG RECEPTOR BINDING; DRUG TARGETING; HORMONE RECEPTOR INTERACTION; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; SEROTONINERGIC SYSTEM;

ANIMALS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; COS CELLS; HYDROLYSIS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PHOSPHATIDYLINOSITOLS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SPIPERONE; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTAMINES;

EID: 0034119969     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Albert PR, Lembo P, Storring JM, Charest A and Saucier C (1996) The 5-HT1A receptor: Signaling, desensitization, and gene transcription. Neuropsychopharmacology 14:19-25.
2. Almaula N, Ebersole BJ, Zhang D, Weinstein H and Sealfon SC (1996) Mapping the binding site pocket of the serotonin 5-hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem 271:14672-14675.
3. Baldwin JM, Schertler GF and Unger VM (1997) An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 272:144-164.
4. Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, Chi L, Millar RP, Davidson JS, Weinstein H and Sealfon SC (1998) Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J Biol Chem 273:10445-10453.
5. Berry SA, Shah M, Khan N and Roth BL (1996) Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol Pharmacol 50:306-313.
6. Boess FG, Monsma FJ Jr and Sleight AJ (1998) Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem 71:2169-2177.
7. Branchek T (1993) Site-directed mutagenesis of serotonin receptors. Med Chem Res 3:287-296.
8. Chanda PK, Minchin MC, Davis AR, Greenberg L, Reilly Y, McGregor WH, Bhat R, Lubeck MD, Mizutani S and Hung PP (1993) Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. Mol Pharmacol 43:516-520.
9. 3H]ketanserin binding to 5-hydroxytryptamine2 receptors. Mol Pharmacol 43:755-761.
10. Choudhary MS, Sachs N, Uluer A, Glennon RA, Westkaemper RB and Roth BL (1995) Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: Ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol 47:450-457.
11. Cohen GB, Oprian DD and Robinson PR (1992) Mechanism of activation and inactivation of opsin: Role of Glu113 and Lys296. Biochemistry 31:12592-12601.
12. Farrens DA, Yang K, Hubbell WL and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274:768-770.
13. Fu DB, Weinstein H, Chen J and Javitch JA (1996) Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. Biochemistry 35:11278-11285.
14. Gether U and Kobilka BK (1998) G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273:17979-17982.
15. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H and Kobilka BK (1997) Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J 16:6737-6747.
16. Heymann J and Subramanian S (1997) Expression, stability and membrane integration of truncation mutants of bovine rhodopsin. Proc Natl Acad Sci USA 94:4966-4971.
17. Ho BY, Karschin A, Branchek T, Davidson N and Lester HA (1992) The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: A site-directed mutation study. FEBS Lett 312:259-262.
18. Kuipers W, Van Wijngaarden I and Ijzerman AP (1994) A model of the serotonin 5-HT1A receptor: Agonist and antagonist binding sites. Drug Des Discov 11:231-249.
19. Munson PJ and Rodbard D (1980) LIGAND: A versatile, computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
20. Perlman JC, Wang W, Bence K Osman R, Gershengorn MC (1997) Interactions between conserved residues in the transmembrane helices 1,2, and 7 of the thyrotropin-releasing hormone receptor. J Biol Chem 272:11937-11942.
21. Porter JE, Hwa J and Perez DM (1996) Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem 271:28318-28323.
22. Porter JE and Perez DM (1999) Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor. Altered pharmacology and rescue of constitutive activity. J Biol Chem 274:34535-34538.
23. Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA and Gether U (1999) Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 56:175-184.
24. Robinson PR, Cohen GB, Zhukovsky EA and Oprian DD (1992) Constitutively active mutants of rhodopsin. Neuron 9:719-725.
25. Rodriguez MC, Xie YB, Wang H, Collison K and Segaloff DL (1992) Effects of truncations of the cytoplasmic tail of the luteinizing hormone/chorionic gonadotropin receptor on receptor-mediated hormone internalization. Mol Endocrinol 6:327-336.
26. Roth BL, Palvimakki E-P, Berry SA, Khan NS, Uluer A and Choudhary MS (1995) 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther 275:1638-1646.
27. Roth BL, Choudhary MS, Khan N and Uluer AZ (1997a) High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: Evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 280:576-583.
28. Roth BL, Shoham M, Choudhary MS and Khan N ( 1997b) Identification of conserved aromatic residues essential for agonist binding and efficacy at 5-HT2A receptors. Mol Pharmacol 52:259-266.
29. Schulein R, Hermosilla R, Oksche A, Dehe M, Wiesner B, Krause G and Rosenthal W (1998) A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS M6 cells. Mol Pharmacol 54:525-535.
30. Schulein R, Liebenhoff U, Muller H, Birnbaumer M and Rosenthal W (1996a) Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. Biochem J 313:611-616.
31. Schulein R, Rutz C and Rosenthal W (1996b) Membrane targeting and determination of transmembrane topology of the human vasopressin V2 receptor. J Biol Chem 271:28844-28852.
32. Sealfon SC, Chi L, Ebersole BJ, Rodic V, Zhang D, Ballesteros JA and Weinstein H (1995) Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem 270:16683-16688.
33. Wang CD, Gallaher TK and Shih JC (1993) Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: Identification of amino acids necessary for ligand binding and receptor activation. Mol Pharmacol 43:931-940.